D. Marco, L. Y. Venneri, A. Farkas, E. Evans, P. C. Marzo et al., Vascular dysfunction in the pathogenesis of Alzheimer's disease-a review of endothelium-mediated mechanisms and ensuing vicious circles, Neurobiol Dis, vol.82, pp.593-606, 2015.

F. J. Díez-guerra, Neurogranin, a link between calcium/ calmodulin and protein kinase C signaling in synaptic plasticity, IUBMB Life, vol.62, pp.597-606, 2010.

G. Disanto, C. Barro, P. Benkert, Y. Naegelin, S. Schädelin et al., Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis, Ann Neurol, vol.81, pp.857-870, 2017.

R. S. Doody, R. G. Thomas, M. Farlow, T. Iwatsubo, B. Vellas et al., Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease, N Engl J Med, vol.370, pp.311-321, 2014.

A. Dorey, A. Perret-liaudet, Y. Tholance, A. Fourier, and I. Quadrio, Cerebrospinal fluid A?40 improves the interpretation of A?42 concentration for diagnosing Alzheimer's disease, Front Neurol, vol.6, p.247, 2015.

E. C. Downes, J. Robson, E. Grailly, Z. Abdel-all, J. Xuereb et al., Loss of synaptophysin and synaptosomal-associated protein 25-kDa (SNAP-25) in elderly down syndrome individuals, Neuropathol Appl Neurobiol, vol.34, pp.12-22, 2008.

B. Dubois, H. H. Feldman, C. Jacova, H. Hampel, J. L. Molinuevo et al., Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria, Lancet Neurol, vol.13, issue.14, pp.70090-70090, 2014.

S. Engelborghs, E. Niemantsverdriet, H. Struyfs, K. Blennow, R. Brouns et al., Consensus guidelines for lumbar puncture in patients with neurological diseases, Alzheimers Dement (Amst), vol.8, pp.111-126, 2017.

, Qualification opinion of Alzheimer's disease novel methodologies/biomarkers for the use of CSF amyloid beta 1-42 and t-tau signature and/or PET-amyloid imaging (positive/negative) as biomarkers for enrichment, for use in regulatory clinical trials in mild and moderate Alzheimer's disease, European Medicines Agency, Committee for Medicinal Products for Human Use, 2011.

, Guideline on the clinical investigation of medicines for the treatment of Alzheimer's disease, European Medicines Agency, Committee for Medicinal Products for Human Use, 2018.

M. Ewers, X. Cheng, Z. Zhong, H. F. Nural, C. Walsh et al., Increased CSF-BACE1 activity associated with decreased hippocampus volume in Alzheimer's disease, J Alzheimers Dis, vol.25, pp.373-381, 2011.

M. Ewers, N. Mattsson, L. Minthon, J. L. Molinuevo, A. Antonell et al., CSF biomarkers for the differential diagnosis of Alzheimer's disease: a large-scale international multicenter study, Alzheimers Dement, vol.11, pp.1306-1315, 2015.

M. Ewers, Z. Zhong, K. Bürger, A. Wallin, K. Blennow et al., Increased CSF-BACE 1 activity is associated with ApoE-?4 genotype in subjects with mild cognitive impairment and Alzheimer's disease, Brain, vol.131, pp.1252-1258, 2008.

A. M. Fagan, M. A. Mintun, R. H. Mach, S. Y. Lee, C. S. Dence et al., Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid A?42 in humans, Ann Neurol, vol.59, pp.512-519, 2006.

J. Goossens, E. Vanmechelen, J. Q. Trojanowski, V. M. Lee, C. Van-broeckhoven et al., TDP-43 as a possible biomarker for frontotemporal lobar degeneration: a systematic review of existing antibodies, Acta Neuropathol Commun, vol.3, p.15, 2015.

K. Goozee, P. Chatterjee, J. I. Shen, K. Sohrabi, H. R. Asih et al., Elevated plasma ferritin in elderly individuals with high neocortical amyloid-beta load, Mol Psychiatry, vol.23, pp.1807-1812, 2018.

S. A. Gravina, L. Ho, C. B. Eckman, K. E. Long, L. Otvos et al., Amyloid beta protein (A beta) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43), J Biol Chem, vol.270, pp.7013-7016, 1995.

T. Grimmer, M. Riemenschneider, H. Förstl, G. Henriksen, W. E. Klunk et al., Beta amyloid in Alzheimer's disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid, Biol Psychiatry, vol.65, pp.927-934, 2009.

M. Groblewska, P. Muszynski, A. Wojtulewska-supron, A. Kulczynska-przybik, and B. Mroczko, The role of visinin-like protein-1 in the pathophysiology of Alzheimer's disease, J Alzheimers Dis, vol.47, pp.17-32, 2015.

R. Guerreiro, A. Wojtas, J. Bras, M. Carrasquillo, E. Rogaeva et al., TREM2 variants in Alzheimer's disease, N Engl J Med, vol.368, pp.117-127, 2013.

A. P. Gunn, C. L. Masters, and R. A. Cherny, Pyroglutamate-A?: role in the natural history of Alzheimer's disease, Int J Biochem Cell Biol, vol.42, pp.1915-1918, 2010.

J. L. Guo and V. M. Lee, Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases, Nat Med, vol.20, pp.130-138, 2014.

L. H. Guo, P. Alexopoulos, and R. Perneczky, Heart-type fatty acid binding protein and vascular endothelial growth factor: cerebrospinal fluid biomarker candidates for Alzheimer's disease, Eur Arch Psychiatry Clin Neurosci, vol.263, pp.553-560, 2013.

R. Guo, G. Fan, J. Zhang, C. Wu, Y. Du et al., A 9-microRNA signature in serum serves as a noninvasive biomarker in early diagnosis of Alzheimer's disease, J Alzheimers Dis, vol.60, pp.1365-1377, 2017.

R. L. Hamilton, Lewy bodies in Alzheimer's disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry, Brain Pathol, vol.10, pp.378-384, 2000.

H. Hampel, K. Bürger, S. J. Teipel, A. L. Bokde, H. Zetterberg et al., Core candidate neurochemical and imaging biomarkers of Alzheimer's disease, Alzheimers Dement, vol.4, pp.38-48, 2008.

H. Hampel, R. Frank, K. Broich, S. J. Teipel, R. G. Katz et al., Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives, Nat Rev Drug Discov, vol.9, pp.560-574, 2010.

H. Hampel, S. Lista, and Z. S. Khachaturian, Development of biomarkers to chart all Alzheimer's disease stages: the royal road to cutting the therapeutic Gordian Knot, Alzheimers Dement, vol.8, pp.312-336, 2012.

H. Hampel, S. Lista, S. J. Teipel, F. Garaci, R. Nisticó et al., Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: a long-range point of view beyond 2020, Biochem Pharmacol, vol.88, pp.426-449, 2014.

H. Hampel, O. Bryant, S. E. Castrillo, J. I. Ritchie, C. Rojkova et al., PRECISION MEDICINE-the Golden Gate for detection, 2016.

, J Prev Alzheimers Dis, vol.3, pp.243-259

H. Hampel, O. Bryant, S. E. Durrleman, S. Younesi, E. Rojkova et al., A precision medicine initiative for Alzheimer's disease: the road ahead to biomarker-guided integrative disease modeling, Climacteric, vol.20, p.66, 2017.

H. Hampel, O. Bryant, S. E. Molinuevo, J. L. Zetterberg, H. Masters et al., Blood-based biomarkers for Alzheimer's disease: mapping the road to the clinic, Nat Rev Neurol, vol.14, pp.639-652, 2018.

H. Hampel, N. Toschi, C. Babiloni, F. Baldacci, K. L. Black et al., Revolution of Alzheimer precision neurology. Passageway of systems biology and neurophysiology, J Alzheimers Dis, vol.64, issue.1, pp.47-105, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01910402

H. Hampel, A. Vergallo, L. F. Aguilar, N. Benda, K. Broich et al., Precision pharmacology for Alzheimer's disease, Pharmacol Res, vol.130, pp.331-365, 2018.
URL : https://hal.archives-ouvertes.fr/hal-02095292

J. Han, K. Pluhackova, and R. A. Böckmann, The multifaceted role of SNARE proteins in membrane fusion, Front Physiol, vol.8, 2017.

O. Hansson, S. Hall, A. Ohrfelt, H. Zetterberg, K. Blennow et al., Levels of cerebrospinal fluid ?-synuclein oligomers are increased in Parkinson's disease with dementia and dementia with Lewy bodies compared to Alzheimer, 2014.

, Alzheimers Res Ther, vol.6, p.25

O. Hansson, H. Zetterberg, P. Buchhave, E. Londos, K. Blennow et al., Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study, Lancet Neurol, vol.5, issue.06, pp.70355-70361, 2006.

J. A. Hardy and G. A. Higgins, Alzheimer's disease: the amyloid cascade hypothesis, Science, vol.256, pp.184-185, 1992.

D. Hare, S. Ayton, A. Bush, and P. Lei, A delicate balance: iron metabolism and diseases of the brain, Front Aging Neurosci, vol.5, p.34, 2013.

Z. He, J. L. Guo, J. D. Mcbride, S. Narasimhan, H. Kim et al., Amyloid-? plaques enhance Alzheimer's brain tau-seeded pathologies by facilitating neuritic plaque tau aggregation, Nat Med, vol.24, pp.29-38, 2018.

O. Heinonen, H. Soininen, H. Sorvari, O. Kosunen, L. Paljärvi et al., Loss of synaptophysin-like immunoreactivity in the hippocampal formation is an early phenomenon in Alzheimer's disease, Neuroscience, vol.64, pp.375-384, 1995.

K. Hellwig, H. Kvartsberg, E. Portelius, U. Andreasson, T. J. Oberstein et al., Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer's disease, Alzheimers Res Ther, vol.7, 2015.

K. Henjum, I. S. Almdahl, V. Årskog, L. Minthon, O. Hansson et al., Cerebrospinal fluid soluble TREM2 in aging and Alzheimer's disease, Alzheimers Res Ther, vol.8, p.17, 2016.

K. Henriksen, O. Bryant, S. E. Hampel, H. Trojanowski, J. Q. Montine et al., The future of blood-based biomarkers for Alzheimer's disease, Alzheimers Dement, vol.10, pp.115-131, 2014.

A. Heslegrave, W. Heywood, R. Paterson, N. Magdalinou, J. Svensson et al., Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease, Mol Neurodegener, vol.11, 2016.

R. Hesse, A. Wahler, P. Gummert, S. Kirschmer, M. Otto et al., Decreased IL-8 levels in CSF and serum of AD patients and negative correlation of MMSE and IL-1?, BMC Neurol, vol.16, p.185, 2016.

M. Hölttä, O. Hansson, U. Andreasson, J. Hertze, L. Minthon et al., Evaluating amyloid-? oligomers in cerebrospinal fluid as a biomarker for Alzheimer's disease, PLoS One, vol.8, p.81, 2013.

M. H. Horrocks, S. F. Lee, S. Gandhi, N. K. Magdalinou, S. W. Chen et al., Single-molecule imaging of individual amyloid protein aggregates in human biofluids, ACS Chem Neurosci, vol.7, pp.399-406, 2016.

N. Hu, M. S. Tan, J. T. Yu, L. Sun, L. Tan et al., Increased expression of TREM2 in peripheral blood of Alzheimer's disease patients, J Alzheimers Dis, vol.38, pp.497-501, 2014.

W. T. Hu, A. Chen-plotkin, S. E. Arnold, M. Grossman, C. M. Clark et al., Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment, Acta Neuropathol, vol.119, pp.669-678, 2010.

X. Huang, C. S. Atwood, M. A. Hartshorn, G. Multhaup, L. E. Goldstein et al., The A beta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction, Biochemistry, vol.38, pp.7609-7616, 1999.

F. Hulstaert, K. Blennow, A. Ivanoiu, H. C. Schoonderwaldt, M. Riemenschneider et al., Improved discrimination of AD patients using ?-amyloid(1-42) and tau levels in CSF, Neurology, vol.52, pp.1555-1562, 1999.

R. A. Huynh and C. Mohan, Alzheimer's disease: biomarkers in the genome, blood, and cerebrospinal fluid, Front Neurol, vol.8, p.102, 2017.

D. Inekci, K. Henriksen, T. Linemann, M. A. Karsdal, A. Habib et al., Serum fragments of tau for the differential diagnosis of Alzheimer's disease, Curr Alzheimer Res, vol.12, pp.829-836, 2015.

M. Ingelsson, Alpha-synuclein oligomers-neurotoxic molecules in Parkinson's disease and other Lewy body disorders, Front Neurosci, vol.10, p.408, 2016.

D. J. Irwin, Tauopathies as clinicopathological entities, Parkinsonism Relat Disord, vol.22, issue.1, pp.29-33, 2016.

M. Isaac, S. Vamvakas, E. Abadie, B. Jonsson, C. Gispen et al., Qualification opinion of novel methodologies in the predementia stage of Alzheimer's disease: cerebro-spinal-fluid related biomarkers for drugs affecting amyloid burden-regulatory considerations by European Medicines Agency focusing in improving benefit/risk in regulatory trials, Eur Neuropsychopharmacol, vol.21, pp.781-788, 2011.

Y. Iturria-medina, R. C. Sotero, P. J. Toussaint, J. M. Mateos-pérez, and A. C. Evans, Alzheimer's Disease Neuroimaging Initiative (2016) Early role of vascular dysregulation on late-onset Alzheimer's disease based on multifactorial data-driven analysis, Nat Commun, vol.7

T. Iwatsubo, A. Odaka, N. Suzuki, H. Mizusawa, N. Nukina et al., Visualization of A?42(43) and A?40 in senile plaques with end-specific A? monoclonals: evidence that an initially deposited species is A?42(43), Neuron, vol.13, pp.45-53, 1994.

C. R. Jack, D. S. Knopman, W. J. Jagust, R. C. Petersen, M. W. Weiner et al., Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers, Lancet Neurol, vol.12, issue.12, pp.70291-70291, 2013.

K. Jackson, G. A. Barisone, E. Diaz, L. W. Jin, C. Decarli et al., Amylin deposition in the brain: a second amyloid in Alzheimer disease, Ann Neurol, vol.74, pp.517-526, 2013.

W. J. Jagust, S. M. Landau, L. M. Shaw, J. Q. Trojanowski, R. A. Koeppe et al., Relationships between biomarkers in aging and dementia, vol.73, pp.1193-1199, 2009.
DOI : 10.1212/wnl.0b013e3181bc010c
URL : http://europepmc.org/articles/pmc2764726?pdf=render

B. D. James, R. S. Wilson, P. A. Boyle, J. Q. Trojanowski, D. A. Bennett et al., TDP-43 stage, mixed pathologies, and clinical Alzheimer's-type dementia, Brain, vol.139, pp.2983-2993, 2016.

S. Janelidze, E. Stomrud, S. Palmqvist, H. Zetterberg, D. Van-westen et al., Plasma ?-amyloid in Alzheimer's disease and vascular disease, Sci Rep, vol.6, p.26801, 2016.

S. Janelidze, H. Zetterberg, N. Mattsson, S. Palmqvist, H. Vanderstichele et al., CSF A?42/A?40 and A?42/ A?38 ratios: better diagnostic markers of Alzheimer disease, vol.3, pp.154-165, 2016.

T. R. Jay, V. E. Saucken, and G. E. Landreth, TREM2 in neurodegenerative diseases, vol.12, p.56, 2017.

K. A. Josephs, J. L. Whitwell, D. S. Knopman, W. T. Hu, D. A. Stroh et al., Abnormal TDP-43 immunoreactivity in AD modifies clinicopathologic and radiologic phenotype, Neurology, vol.70, pp.1850-1857, 2008.

M. Jucker and L. C. Walker, Self-propagation of pathogenic protein aggregates in neurodegenerative diseases, Nature, vol.501, pp.45-51, 2013.

A. Junttila, M. Kuvaja, P. Hartikainen, M. Siloaho, S. Helisalmi et al., Cerebrospinal fluid TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis patients with and without the C9ORF72 hexanucleotide expansion, Dement Geriatr Cogn Dis Extra, vol.6, pp.142-149, 2016.

N. Kakuda, T. Miyasaka, N. Iwasaki, T. Nirasawa, S. Wada-kakuda et al., Distinct deposition of amyloid-beta species in brains with Alzheimer's disease pathology visualized with MALDI imaging mass spectrometry, Acta Neuropathol Commun, vol.5, p.73, 2017.

P. K. Kamat, A. Kalani, S. Rai, S. Swarnkar, S. Tota et al., Mechanism of oxidative stress and synapse dysfunction in the pathogenesis of Alzheimer's disease: understanding the therapeutics strategies, Mol Neurobiol, vol.53, pp.648-661, 2016.

J. H. Kang, D. J. Irwin, A. S. Chen-plotkin, A. Siderowf, C. Caspell et al., Association of cerebrospinal fluid ?-amyloid 1-42, t-tau, p-tau181, and ?-synuclein levels with clinical features of drug-naive patients with early Parkinson disease, JAMA Neurol, vol.70, pp.1277-1287, 2013.

J. H. Kang, B. Mollenhauer, C. S. Coffey, J. B. Toledo, D. Weintraub et al., CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study, Acta Neuropathol, vol.131, pp.935-949, 2016.

E. Kapaki, G. P. Paraskevas, E. Emmanouilidou, and K. Vekrellis, The diagnostic value of CSF ?-synuclein in the differential diagnosis of dementia with Lewy bodies vs. normal subjects and patients with Alzheimer's disease, PLoS One, vol.8, 2013.

T. Kasai, T. Tokuda, R. Ishii, N. Ishigami, Y. Tsuboi et al., Increased ?-synuclein levels in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease, J Neurol, vol.261, pp.1203-1209, 2014.

K. Kasuga, T. Tokutake, A. Ishikawa, T. Uchiyama, T. Tokuda et al., Differential levels of ?-synuclein, ?-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease, J Neurol Neurosurg Psychiatry, vol.81, pp.608-610, 2010.

M. E. Kennedy, A. W. Stamford, X. Chen, K. Cox, J. N. Cumming et al., The BACE1 inhibitor verubecestat (MK-8931) reduces CNS ?-amyloid in animal models and in Alzheimer's disease patients, Sci Transl Med, vol.8, pp.363-150, 2016.

G. Kerchner, G. Ayalon, M. Blendstrup, F. Brunstein, P. Chandra et al., Targeting tau with RO7105705: Phase I results and design of a Phase II study in prodromal-to-mild AD. Abstract presented at the 10th Clinical Trials on Alzheimer's Disease (CTAD), pp.1-4, 2017.

M. I. Kester, C. E. Teunissen, D. L. Crimmins, E. M. Herries, J. H. Ladenson et al., Neurogranin as a cerebrospinal fluid biomarker for synaptic loss in symptomatic Alzheimer disease, JAMA Neurol, vol.72, pp.1275-1280, 2015.

M. I. Kester, C. E. Teunissen, C. Sutphen, E. M. Herries, J. H. Ladenson et al., Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer's disease in a memory clinic cohort, Alzheimers Res Ther, vol.7, 2015.

S. S. Khan and G. S. Bloom, Tau: the center of a signaling nexus in Alzheimer's disease, Front Neurosci, vol.10, p.31, 2016.

D. Kim, Y. S. Kim, D. W. Shin, C. S. Park, and J. H. Kang, Harnessing cerebrospinal fluid biomarkers in clinical trials for treating Alzheimer's and Parkinson's diseases: potential and challenges, J Clin Neurol, vol.12, pp.381-392, 2016.

H. J. Kim, K. W. Park, T. E. Kim, J. Y. Im, H. S. Shin et al., Elevation of the plasma A?40/A?42 ratio as a diagnostic marker of sporadic early-onset Alzheimer's disease, J Alzheimers Dis, vol.48, pp.1043-1050, 2015.

J. Kim, L. Onstead, S. Randle, R. Price, L. Smithson et al., A?40 inhibits amyloid deposition in vivo, J Neurosci, vol.27, pp.627-633, 2007.

W. S. Kim, K. Kågedal, and G. M. Halliday, Alpha-synuclein biology in Lewy body diseases, Alzheimers Res Ther, vol.6, p.73, 2014.

M. Komori, P. Kosa, J. Stein, V. Zhao, A. Blake et al., Pharmacodynamic effects of daclizumab in the intrathecal compartment, Ann Clin Transl Neurol, vol.4, pp.478-490, 2017.

A. Korff, C. Liu, C. Ginghina, M. Shi, and J. Zhang, Initiative Alzheimer's Disease Neuroimaging (2013) ?-Synuclein in cerebrospinal fluid of Alzheimer's disease and mild cognitive impairment, J Alzheimers Dis, vol.36, pp.679-688

J. Kuhle, B. Nourbakhsh, D. Grant, S. Morant, C. Barro et al., Serum neurofilament is associated with progression of brain atrophy and disability in early MS, Neurology, vol.88, p.3, 2017.

J. Kuhlmann, U. Andreasson, J. Pannee, M. Bjerke, E. Portelius et al., Abeta1-42-an excellent but complicated Alzheimer's biomarker-a route to standardisation, Clin Chim Acta, vol.467, pp.27-33, 2017.

P. H. Kuhn, K. Koroniak, S. Hogl, A. Colombo, U. Zeitschel et al., Secretome protein enrichment identifies physiological BACE1 protease substrates in neurons, EMBO J, vol.31, pp.3157-3168, 2012.

H. B. Kuiperij, A. A. Versleijen, M. Beenes, N. A. Verwey, L. Benussi et al., Tau rather than TDP-43 proteins are potential cerebrospinal fluid biomarkers for frontotemporal lobar degeneration subtypes: a pilot study, J Alzheimers Dis, vol.55, pp.585-595, 2017.

I. Kuperstein, K. Broersen, I. Benilova, J. Rozenski, W. Jonckheere et al., Neurotoxicity of Alzheimer's disease A? peptides is induced by small changes in the A?42 to A?40 ratio, EMBO J, vol.29, pp.3408-3420, 2010.

H. Kvartsberg, F. H. Duits, M. Ingelsson, N. Andreasen, A. Öhrfelt et al., Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease, Alzheimers Dement, vol.11, pp.1180-1190, 2015.

H. Kvartsberg, E. Portelius, U. Andreasson, G. Brinkmalm, K. Hellwig et al., Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer's disease patients and healthy controls, Alzheimers Res Ther, vol.7, 2015.

K. Lai, C. S. Liu, A. Rau, K. L. Lanctot, C. A. Kohler et al., Peripheral inflammatory markers in Alzheimer's disease: a systematic review and meta-analysis of 175 studies, J Neurol Neurosurg Psychiatry, vol.88, pp.876-882, 2017.

O. F. Laterza, V. R. Modur, D. L. Crimmins, J. V. Olander, Y. Landt et al., Identification of novel brain biomarkers, Clin Chem, vol.52, pp.1713-1721, 2006.

C. Lauridsen, S. B. Sando, I. Moller, G. Berge, P. K. Pomary et al., Cerebrospinal fluid Abeta43 Is reduced in early-onset compared to late-onset Alzheimer's Disease, but has similar diagnostic accuracy to Abeta42, Front Aging Neurosci, vol.9, 2017.

J. M. Lee, K. Blennow, N. Andreasen, O. Laterza, V. Modur et al., The brain injury biomarker VLP-1 is increased in the cerebrospinal fluid of Alzheimer disease patients, Clin Chem, vol.54, pp.1617-1623, 2008.

P. H. Lee, G. Lee, H. J. Park, O. Y. Bang, I. S. Joo et al., The plasma alpha-synuclein levels in patients with Parkinson's disease and multiple system atrophy, J Neural Transm, vol.113, pp.1435-1439, 2006.

V. M. Lee, B. J. Balin, L. Otvos, and J. Q. Trojanowski, A68: a major subunit of paired helical filaments and derivatized forms of normal tau, Science, vol.251, pp.675-678, 1991.

V. M. Lee and J. Q. Trojanowski, Transgenic mouse models of tauopathies: prospects for animal models of Pick's disease, Neurology, vol.56, pp.26-30, 2001.

M. J. Leitão, I. Baldeiras, S. K. Herukka, M. Pikkarainen, V. Leinonen et al., Chasing the effects of pre-analytical confounders-a multicenter study on CSF-AD biomarkers, Front Neurol, vol.6, p.153, 2015.

A. W. Lemstra, M. H. De-beer, C. E. Teunissen, C. Schreuder, P. Scheltens et al., Concomitant AD pathology affects clinical manifestation and survival in dementia with Lewy bodies, J Neurol Neurosurg Psychiatry, vol.88, pp.113-118, 2017.

J. Leschik, A. Welzel, C. Weissmann, A. Eckert, and R. Brandt, Inverse and distinct modulation of tau-dependent neurodegeneration by presenilin 1 and amyloid-? in cultured cortical neurons: evidence that tau phosphorylation is the limiting factor in amyloid-?-induced cell death, J Neurochem, vol.101, pp.1303-1315, 2007.

Y. Y. Leung, J. B. Toledo, A. Nefedov, R. Polikar, N. Raghavan et al., Identifying amyloid pathology-related cerebrospinal fluid biomarkers for Alzheimer's disease in a multicohort study, Alzheimers Dement (Amst), vol.1, pp.339-348, 2015.

A. Leuzy, K. Chiotis, S. G. Hasselbalch, J. O. Rinne, A. De-mendonça et al., Pittsburgh compound B imaging and cerebrospinal fluid amyloid-? in a multicentre European memory clinic study, Brain, vol.139, pp.2540-2553, 2016.

J. B. Leverenz, M. A. Fishel, E. R. Peskind, T. J. Montine, D. Nochlin et al., Lewy body pathology in familial Alzheimer disease: evidence for disease-and mutation-specific pathologic phenotype, Arch Neurol, vol.63, pp.370-376, 2006.

P. Lewczuk, N. Lelental, I. Lachmann, M. Holzer, K. Flach et al., Non-phosphorylated tau as a potential biomarker of Alzheimer's disease: analytical and diagnostic characterization, J Alzheimers Dis, vol.55, pp.159-170, 2017.

P. Lewczuk, A. Matzen, K. Blennow, L. Parnetti, J. L. Molinuevo et al., Cerebrospinal fluid A?42/40 corresponds better than A?42 to amyloid PET in Alzheimer's disease, J Alzheimers Dis, vol.55, pp.813-822, 2017.

P. Lewczuk, P. Riederer, O. Bryant, S. E. Verbeek, M. M. Dubois et al., Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: an update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry, World J Biol Psychiatry, p.56, 2017.

K. A. Lewis, Y. Su, O. Jou, C. Ritchie, C. Foong et al., Abnormal neurites containing C-terminally truncated alpha-synuclein are present in Alzheimer's disease without conventional Lewy body pathology, Am J Pathol, vol.177, pp.3037-3050, 2010.

T. Leyhe, N. Andreasen, M. Simeoni, A. Reich, V. Arnim et al., Modulation of beta-amyloid by a single dose of GSK933776 in patients with mild Alzheimer's disease: a phase I study, Alzheimers Res Ther, vol.6, p.19, 2014.

G. Li, I. Sokal, J. F. Quinn, J. B. Leverenz, M. Brodey et al., CSF tau/A?42 ratio for increased risk of mild cognitive impairment: a follow-up study, Neurology, vol.69, pp.631-639, 2007.

X. Li, P. Lei, Q. Tuo, S. Ayton, Q. X. Li et al., Enduring elevations of hippocampal amyloid precursor protein and iron are features of ?-amyloid toxicity and are mediated by tau, Neurotherapeutics, vol.12, pp.862-873, 2015.

S. Libreros and V. Iragavarapu-charyulu, YKL-40/CHI3L1 drives inflammation on the road of tumor progression, J Leukoc Biol, vol.98, pp.931-936, 2015.

C. H. Lin, S. Y. Yang, H. E. Horng, C. C. Yang, J. J. Chieh et al., Plasma ?-synuclein predicts cognitive decline in Parkinson's disease, J Neurol Neurosurg Psychiatry, vol.88, pp.818-824, 2017.

C. F. Lippa, M. L. Schmidt, V. M. Lee, and J. Q. Trojanowski, Antibodies to alpha-synuclein detect Lewy bodies in many Down's syndrome brains with Alzheimer's disease, Ann Neurol, vol.45, pp.353-357, 1999.

S. Lista and E. Emanuele, Role of amyloid beta1-42 and neuroimaging biomarkers in Alzheimer's disease, Biomark Med, vol.5, pp.411-413, 2011.

S. Lista, F. Faltraco, and H. Hampel, Biological and methodical challenges of blood-based proteomics in the field of neurological research, Prog Neurobiol, vol.101, pp.18-34, 2013.

S. Lista, F. Faltraco, D. Prvulovic, and H. Hampel, Blood and plasma-based proteomic biomarker research in Alzheimer's disease, Prog Neurobiol, vol.101, pp.1-17, 2013.
DOI : 10.1016/j.pneurobio.2012.06.007

S. Lista, F. G. Garaci, M. Ewers, S. Teipel, H. Zetterberg et al., CSF Abeta1-42 combined with neuroimaging biomarkers in the early detection, diagnosis and prediction of Alzheimer's disease, Alzheimers Dement, vol.10, pp.381-392, 2014.

S. Lista and H. Hampel, Synaptic degeneration and neurogranin in the pathophysiology of Alzheimer's disease, Expert Rev Neurother, vol.17, pp.47-57, 2017.

S. Lista, Z. S. Khachaturian, D. Rujescu, F. Garaci, B. Dubois et al., Application of systems theory in longitudinal studies on the origin and progression of Alzheimer's disease, Methods Mol Biol, vol.1303, pp.49-67, 2016.

S. Lista, N. Toschi, F. Baldacci, H. Zetterberg, K. Blennow et al., Diagnostic accuracy of CSF neurofilament light chain protein in the biomarker-guided classification system for Alzheimer's disease, Neurochem Int, vol.108, pp.355-360, 2017.

S. Lista, N. Toschi, F. Baldacci, H. Zetterberg, K. Blennow et al., Cerebrospinal fluid neurogranin as a biomarker of neurodegenerative diseases: a cross-sectional study, J Alzheimers Dis, vol.59, pp.1327-1334, 2017.

S. Lista, H. Zetterberg, O. Bryant, S. E. Blennow, K. Hampel et al., Evolving relevance of neuroproteomics in Alzheimer's disease, Methods Mol Biol, vol.1598, pp.101-115, 2017.

M. Liu, S. Guo, J. M. Hibbert, V. Jain, N. Singh et al., CXCL10/IP-10 in infectious diseases pathogenesis and potential therapeutic implications, Cytokine Growth Factor Rev, vol.22, pp.121-130, 2011.

J. Ljungqvist, H. Zetterberg, M. Mitsis, K. Blennow, and T. Skoglund, Serum neurofilament light protein as a marker for diffuse axonal injury: results from a case series study, J Neurotrauma, vol.34, pp.1124-1127, 2017.
DOI : 10.1089/neu.2016.4496
URL : http://discovery.ucl.ac.uk/1537975/1/Zetterberg_Ljungqvist.pdf

F. Llorens, N. Kruse, A. Karch, M. Schmitz, S. Zafar et al., Validation of ?-synuclein as a CSF biomarker for sporadic Creutzfeldt-Jakob disease, Mol Neurobiol, vol.55, pp.2249-2257, 2017.

D. A. Loeffler, J. R. Connor, P. L. Juneau, B. S. Snyder, L. Kanaley et al., Transferrin and iron in normal, Alzheimer's disease, and Parkinson's disease brain regions, J Neurochem, vol.65, pp.710-724, 1995.

H. Lövheim, F. Elgh, A. Johansson, H. Zetterberg, K. Blennow et al., Plasma concentrations of free amyloid ? cannot predict the development of Alzheimer's disease, Alzheimers Dement, vol.13, pp.778-782, 2017.

C. H. Lu, C. Macdonald-wallis, G. E. Pearce, N. Petzold, A. Norgren et al., Neurofilament light chain: a prognostic biomarker in amyotrophic lateral sclerosis, Neurology, vol.84, pp.2247-2257, 2015.
DOI : 10.1212/wnl.0000000000001642
URL : http://n.neurology.org/content/84/22/2247.full.pdf

K. C. Luk, V. Kehm, J. Carroll, B. Zhang, P. O'brien et al., Pathological ?-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice, Science, vol.338, pp.949-953, 2012.
DOI : 10.1126/science.1227157
URL : http://europepmc.org/articles/pmc3552321?pdf=render

X. Luo, L. Hou, H. Shi, X. Zhong, Y. Zhang et al., CSF levels of the neuronal injury biomarker visinin-like protein-1 in Alzheimer's disease and dementia with Lewy bodies, J Neurochem, vol.127, pp.681-690, 2013.

J. N. Lycke, J. E. Karlsson, O. Andersen, and L. E. Rosengren, Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis, J Neurol Neurosurg Psychiatry, vol.64, pp.402-404, 1998.

N. K. Majbour, D. Chiasserini, N. N. Vaikath, P. Eusebi, T. Tokuda et al., Increased levels of CSF total but not oligomeric or phosphorylated forms of alpha-synuclein in patients diagnosed with probable Alzheimer's disease, Sci Rep, vol.7, 2017.

N. K. Majbour, N. N. Vaikath, K. D. Van-dijk, M. T. Ardah, S. Varghese et al., Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson's disease, Mol Neurodegener, vol.11, 2016.
DOI : 10.1186/s13024-016-0072-9
URL : https://molecularneurodegeneration.biomedcentral.com/track/pdf/10.1186/s13024-016-0072-9

S. E. Marsh and M. Blurton-jones, Examining the mechanisms that link ?-amyloid and ?-synuclein pathologies, Alzheimers Res Ther, vol.4, p.11, 2012.
DOI : 10.1186/alzrt109
URL : https://alzres.biomedcentral.com/track/pdf/10.1186/alzrt109

E. Masliah, L. Hansen, T. Albright, M. Mallory, and R. D. Terry, Immunoelectron microscopic study of synaptic pathology in Alzheimer's disease, Acta Neuropathol, vol.81, pp.428-433, 1991.

E. Masliah, M. Mallory, M. Alford, R. Deteresa, L. A. Hansen et al., Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease, Neurology, vol.56, pp.127-129, 2001.

E. Masliah, R. D. Terry, M. Alford, R. Deteresa, and L. A. Hansen, Cortical and subcortical patterns of synaptophysinlike immunoreactivity in Alzheimer's disease, Am J Pathol, vol.138, pp.235-246, 1991.

C. L. Masters, R. Bateman, K. Blennow, C. C. Rowe, R. A. Sperling et al., Alzheimer's disease, Nat Rev Dis Primers, vol.1, p.15056, 2015.
URL : https://hal.archives-ouvertes.fr/inserm-01723790

C. L. Masters, G. Simms, N. A. Weinman, G. Multhaup, B. L. Mcdonald et al., Amyloid plaque core protein in Alzheimer disease and Down syndrome, Proc Natl Acad Sci, vol.82, pp.4245-4249, 1985.

N. Mattsson, U. Andreasson, H. Zetterberg, and K. Blennow, Alzheimer's Disease Neuroimaging Initiative (2017) Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease, JAMA Neurol, vol.74, pp.557-566

N. Mattsson, M. C. Carrillo, R. A. Dean, M. D. Devous, . Sr et al., Revolutionizing Alzheimer's disease and clinical trials through biomarkers, Alzheimers Dement (Amst), vol.1, pp.412-419, 2015.

N. Mattsson, P. S. Insel, S. Palmqvist, E. Portelius, H. Zetterberg et al., Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease, EMBO Mol Med, vol.8, pp.1184-1196, 2016.

N. Mattsson, P. S. Insel, S. Palmqvist, E. Stomrud, D. Van-westen et al., , 2016.

, Nat Commun, vol.7

N. Mattsson, S. Tabatabaei, P. Johansson, O. Hansson, U. Andreasson et al., Cerebrospinal fluid microglial markers in Alzheimer's disease: elevated chitotriosidase activity but lack of diagnostic utility, Neuromol Med, vol.13, pp.151-159, 2011.

N. Mattsson, H. Zetterberg, S. Janelidze, P. S. Insel, U. Andreasson et al., Plasma tau in Alzheimer disease. Neurology, vol.87, pp.1827-1835, 2016.

E. Mcgowan, F. Pickford, J. Kim, L. Onstead, J. Eriksen et al., A?42 is essential for parenchymal and vascular amyloid deposition in mice, Neuron, vol.47, pp.191-199, 2005.

G. M. Mckhann, D. S. Knopman, H. Chertkow, B. T. Hyman, C. R. Jack et al., The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimers Dement, vol.7, pp.263-269, 2011.

P. D. Mehta, T. Pirttila, S. P. Mehta, E. A. Sersen, P. S. Aisen et al., Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease, Arch Neurol, vol.57, pp.100-105, 2000.

J. Mellergård, A. Tisell, I. Blystad, A. Grönqvist, K. Blennow et al., Cerebrospinal fluid levels of neurofilament and tau correlate with brain atrophy in natalizumab-treated multiple sclerosis, Eur J Neurol, vol.24, pp.112-121, 2017.

J. E. Meredith, S. Sankaranarayanan, V. Guss, A. J. Lanzetti, F. Berisha et al., Characterization of novel CSF tau and ptau biomarkers for Alzheimer's disease, PLoS One, vol.8, p.23, 2013.

M. M. Mielke, C. E. Hagen, A. Wennberg, D. C. Airey, R. Savica et al., Association of plasma total tau level with cognitive decline and risk of mild cognitive impairment or dementia in the Mayo Clinic Study on Aging, JAMA Neurol, vol.74, pp.1073-1080, 2017.

N. Mohorko and M. Bresjanac, Tau protein and human tauopathies: an overview, Zdrav Vestn, vol.77, pp.35-41, 2008.

B. Mollenhauer, V. Cullen, I. Kahn, B. Krastins, T. F. Outeiro et al., Direct quantification of CSF ?-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration, Exp Neurol, vol.213, pp.315-325, 2008.

B. Mollenhauer, P. Steinacker, E. Bahn, M. Bibl, P. Brechlin et al., Serum heart-type fatty acidbinding protein and cerebrospinal fluid tau: marker candidates for dementia with Lewy bodies, Neurodegener Dis, vol.4, pp.366-375, 2007.

Y. Mori, Y. Yoshino, S. Ochi, K. Yamazaki, K. Kawabe et al., TREM2 mRNA expression in leukocytes is increased in Alzheimer's disease and schizophrenia, PLoS One, vol.10, p.35, 2015.

R. Motter, C. Vigo-pelfrey, D. Kholodenko, R. Barbour, K. Johnsonwood et al., Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease, Ann Neurol, vol.38, pp.643-648, 1995.

B. Mroczko, M. Groblewska, M. Zboch, P. Muszynski, A. Zajkowska et al., Evaluation of visinin-like protein 1 concentrations in the cerebrospinal fluid of patients with mild cognitive impairment as a dynamic biomarker of Alzheimer's disease, J Alzheimers Dis, vol.43, pp.1031-1037, 2015.

S. D. Mulder, W. M. Van-der-flier, J. H. Verheijen, C. Mulder, P. Scheltens et al., BACE1 activity in cerebrospinal fluid and its relation to markers of AD pathology, J Alzheimers Dis, vol.20, pp.253-260, 2010.

E. Mulugeta, E. Londos, C. Ballard, G. Alves, H. Zetterberg et al., CSF amyloid ?38 as a novel diagnostic marker for dementia with Lewy bodies, J Neurol Neurosurg Psychiatry, vol.82, pp.160-164, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00589971

A. C. Naj and G. D. Schellenberg, Alzheimer's Disease Genetics Consortium (2017) Genomic variants, genes, and pathways of Alzheimer's disease: an overview, Am J Med Genet B Neuropsychiatr Genet, vol.174, pp.5-26

A. Nakamura, N. Kaneko, V. L. Villemagne, T. Kato, J. Doecke et al., High performance plasma amyloid-? biomarkers for Alzheimer's disease, Nature, vol.554, pp.249-254, 2018.

S. Nath, A. Koziarz, J. H. Badhiwala, W. Alhazzani, R. Jaeschke et al., Atraumatic versus conventional lumbar puncture needles: a systematic review and meta-analysis, Lancet, vol.391, issue.17, pp.32451-32451, 2017.

P. T. Nelson, I. Alafuzoff, E. H. Bigio, C. Bouras, H. Braak et al., Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature, J Neuropathol Exp Neurol, vol.71, pp.362-381, 2012.

K. Neumann, G. Farías, A. Slachevsky, P. Perez, and R. B. Maccioni, Human platelets tau: a potential peripheral marker for Alzheimer's disease, J Alzheimers Dis, vol.25, pp.103-109, 2011.

M. Neumann, D. M. Sampathu, L. K. Kwong, A. C. Truax, M. C. Micsenyi et al., Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis, Science, vol.314, pp.130-133, 2006.

L. Novakova, M. Axelsson, M. Khademi, H. Zetterberg, K. Blennow et al., Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsingremitting multiple sclerosis, J Neurochem, vol.141, pp.296-304, 2017.

L. Novakova, M. Axelsson, M. Khademi, H. Zetterberg, K. Blennow et al., Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis, Mult Scler, vol.23, pp.62-71, 2017.

O. Bryant, S. E. Gupta, V. Henriksen, K. Edwards, M. Jeromin et al., Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research, Alzheimers Dement, vol.11, pp.549-560, 2015.

O. Bryant, S. E. Mielke, M. M. Rissman, R. A. Lista, S. Vanderstichele et al., Blood-based biomarkers in Alzheimer disease: current state of the science and a novel collaborative paradigm for advancing from discovery to clinic, Alzheimers Dement, vol.13, pp.45-58, 2017.

A. Öhrfelt, A. Brinkmalm, J. Dumurgier, G. Brinkmalm, O. Hansson et al., The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer's disease. Alzheimers Res Ther, vol.8, p.41, 2016.

B. Olsson, R. Lautner, U. Andreasson, A. Öhrfelt, E. Portelius et al., CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis, Lancet Neurol, vol.15, issue.16, pp.70-73, 2016.

F. Olsson, S. Schmidt, V. Althoff, L. M. Munter, J. S. Rosqvist et al., Characterization of intermediate steps in amyloid beta (A?) production under near-native conditions, J Biol Chem, vol.289, pp.1540-1550, 2014.

V. Ovod, K. N. Ramsey, K. G. Mawuenyega, J. G. Bollinger, T. Hicks et al., Amyloid ? concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis, Alzheimers Dement, vol.13, pp.841-849, 2017.

S. Palmqvist, S. Janelidze, E. Stromrud, H. Zetterberg, J. Karl et al., Detecting brain amyloid status using fully automated plasma A? biomarker assays, Abstract presented at the Alzheimer's Association International Conference (AAIC) 2018. Chicago, pp.22-26, 2018.

S. Palmqvist, H. Zetterberg, N. Mattsson, and P. Johansson, Alzheimer's Disease Neuroimaging Initiative, Minthon L et al (2015) Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease, Neurology, vol.85, p.1

J. Pannee, E. Portelius, L. Minthon, J. Gobom, U. Andreasson et al., Reference measurement procedure for CSF amyloid beta (A?)1-42 and the CSF A?1-42/A?1-40 ratio-a cross-validation study against amyloid PET, J Neurochem, vol.139, pp.651-658, 2016.

J. Pannee, U. Törnqvist, A. Westerlund, M. Ingelsson, L. Lannfelt et al., The amyloid-? degradation pattern in plasma-a possible tool for clinical trials in Alzheimer's disease, Neurosci Lett, vol.573, pp.7-12, 2014.

J. C. Park, S. H. Han, H. J. Cho, M. S. Byun, D. Yi et al., Chemically treated plasma A? is a potential blood-based biomarker for screening cerebral amyloid deposition, Alzheimers Res Ther, vol.9, p.20, 2017.

L. Parnetti, P. Eusebi, and A. Lleó, Cerebrospinal fluid biomarkers for target engagement and efficacy in clinical trials for Alzheimer's and Parkinson's diseases, Front Neurol Neurosci, vol.39, pp.117-123, 2016.

T. A. Pascoal, S. Mathotaarachchi, M. Shin, A. L. Benedet, S. Mohades et al., Synergistic interaction between amyloid and tau predicts the progression to dementia, Alzheimers Dement, vol.13, pp.644-653, 2017.

J. B. Pereira, T. O. Strandberg, S. Palmqvist, G. Volpe, D. Van-westen et al., Amyloid network topology characterizes the progression of Alzheimer's disease during the predementia stages, Cereb Cortex, vol.28, pp.340-349, 2018.

J. B. Pereira, E. Westman, and O. Hansson, Alzheimer's Disease Neuroimaging Initiative (2017) Association between cerebrospinal fluid and plasma neurodegeneration biomarkers with brain atrophy in Alzheimer's disease, Neurobiol Aging, vol.58, pp.14-29

R. Perneczky and P. Alexopoulos, Alzheimer's Disease Neuroimaging Initiative (2014) Cerebrospinal fluid BACE1 activity and markers of amyloid precursor protein metabolism and axonal degeneration in Alzheimer's disease, Alzheimers Dement, vol.10, pp.425-429

A. Perret-liaudet, M. Pelpel, Y. Tholance, B. Dumont, H. Vanderstichele et al., Risk of Alzheimer's disease biological misdiagnosis linked to cerebrospinal collection tubes, J Alzheimers Dis, vol.31, pp.13-20, 2012.

R. C. Petersen, P. Aisen, B. F. Boeve, Y. E. Geda, R. J. Ivnik et al., Mild cognitive impairment due to Alzheimer disease in the community, Ann Neurol, vol.74, pp.199-208, 2013.

A. Petzold, G. Keir, J. Warren, N. Fox, and M. N. Rossor, A systematic review and meta-analysis of CSF neurofilament protein levels as biomarkers in dementia, Neurodegener Dis, vol.4, pp.185-194, 2007.

L. Piccio, Y. Deming, J. L. Del-Águila, L. Ghezzi, D. M. Holtzman et al., Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status, Acta Neuropathol, vol.131, pp.925-933, 2016.

Y. A. Pijnenburg, J. C. Janssen, N. S. Schoonenboom, A. Petzold, C. Mulder et al., CSF neurofilaments in frontotemporal dementia compared with early onset Alzheimer's disease and controls, Dement Geriatr Cogn Disord, vol.23, pp.225-230, 2007.

E. Portelius, E. Price, G. Brinkmalm, M. Stiteler, M. Olsson et al., A novel pathway for amyloid precursor protein processing, Neurobiol Aging, vol.32, pp.1090-1098, 2011.

E. Portelius, A. Westman-brinkmalm, H. Zetterberg, and K. Blennow, Determination of ?-amyloid peptide signatures in cerebrospinal fluid using immunoprecipitation-mass spectrometry, 2006.

, J Proteome Res, vol.5, pp.1010-1016

E. Portelius, H. Zetterberg, T. Skillback, U. Tornqvist, U. Andreasson et al., Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease, Brain, vol.138, pp.3373-3385, 2015.

G. Pottiez, L. Yang, T. Stewart, N. Song, P. Aro et al., Mass-spectrometry-based method to quantify in parallel tau and amyloid beta 1-42 in CSF for the diagnosis of Alzheimer's disease, J Proteome Res, vol.16, pp.1228-1238, 2017.

M. Querol-vilaseca, M. Colom-cadena, J. Pegueroles, S. Martínpaniello, C. Clarimon et al., Chitinase 3-like I) is expressed in a subset of astrocytes in Alzheimer's disease and other tauopathies, J Neuroinflammation, vol.14, p.118, 2017.

A. M. Racine, R. L. Koscik, C. R. Nicholas, L. R. Clark, O. C. Okonkwo et al., Cerebrospinal fluid ratios with A?42 predict preclinical brain ?-amyloid accumulation, Alzheimers Dement (Amst), vol.2, pp.27-38, 2016.

E. M. Reiman, Alzheimer disease in 2016: putting AD treatments and biomarkers to the test, Nat Rev Neurol, vol.13, pp.74-76, 2017.

J. A. Rhodin and T. Thomas, A vascular connection to Alzheimer's disease, Microcirculation, vol.8, pp.207-220, 2001.

M. Riemenschneider, S. Wagenpfeil, H. Vanderstichele, M. Otto, J. Wiltfang et al., Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias, Mol Psychiatry, vol.8, pp.343-347, 2003.

A. Ritter and J. Cummings, Fluid biomarkers in clinical trials of Alzheimer's disease therapeutics, Front Neurol, vol.6, p.186, 2015.

A. Rivero-santana, D. Ferreira, L. Perestelo-pérez, E. Westman, L. O. Wahlund et al., Cerebrospinal fluid biomarkers for the differential diagnosis between Alzheimer's disease and frontotemporal lobar degeneration: systematic review, HSROC analysis, and confounding factors, J Alzheimers Dis, vol.55, pp.625-644, 2017.

J. Robinson, E. Lee, S. Xie, L. Rennert, E. Suh et al., Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated, Brain, vol.141, pp.2181-2193, 2018.

C. M. Roe, A. M. Fagan, E. A. Grant, J. Hassenstab, K. L. Moulder et al., Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later, Neurology, vol.80, pp.1784-1791, 2013.

J. C. Rojas, A. Karydas, J. Bang, R. M. Tsai, K. Blennow et al., Plasma neurofilament light chain predicts progression in progressive supranuclear palsy, Ann Clin Transl Neurol, vol.3, pp.216-225, 2016.

C. Rosén, C. H. Andersson, U. Andreasson, J. L. Molinuevo, M. Bjerke et al., Increased levels of chitotriosidase and YKL-40 in cerebrospinal fluid from patients with Alzheimer's disease, Dement Geriatr Cogn Dis Extra, vol.4, pp.297-304, 2014.

P. Roussos, P. Katsel, P. Fam, W. Tan, D. P. Purohit et al., The triggering receptor expressed on myeloid cells 2 (TREM2) is associated with enhanced inflammation, neuropathological lesions and increased risk for Alzheimer's dementia, Alzheimers Dement, vol.11, pp.1163-1170, 2015.

C. C. Rowe, P. Bourgeat, K. A. Ellis, B. Brown, Y. Y. Lim et al., Predicting Alzheimer disease with ?-amyloid imaging: results from the Australian Imaging, Biomarkers, and Lifestyle Study of Ageing, Ann Neurol, vol.74, pp.905-913, 2013.

C. L. Russell, V. Mitra, K. Hansson, K. Blennow, J. Gobom et al., Comprehensive quantitative profiling of tau and phosphorylated tau peptides in cerebrospinal fluid by mass spectrometry provides new biomarker candidates, J Alzheimers Dis, vol.55, pp.303-313, 2017.

A. Salminen, A. Kauppinen, and K. Kaarniranta, Hypoxia/ ischemia activate processing of amyloid precursor protein: impact of vascular dysfunction in the pathogenesis of Alzheimer's disease, J Neurochem, vol.140, pp.536-549, 2017.

N. Salvadores, M. Shahnawaz, E. Scarpini, F. Tagliavini, and C. Soto, Detection of misfolded A? oligomers for sensitive biochemical diagnosis of Alzheimer's disease, Cell Rep, vol.7, pp.261-268, 2014.

A. Sanabria-castro, I. Alvarado-echeverría, and C. Monge-bonilla, Molecular pathogenesis of Alzheimer's disease: an update, Ann Neurosci, vol.24, pp.46-54, 2017.

C. Sanfilippo, O. Forlenza, H. Zetterberg, and K. Blennow, Increased neurogranin concentrations in cerebrospinal fluid of Alzheimer's disease and in mild cognitive impairment due to AD, J Neural Transm, vol.123, pp.1443-1447, 2016.

M. J. Savage, D. J. Holder, G. Wu, J. Kaplow, J. A. Siuciak et al., Soluble BACE-1 activity and sA?PP? concentrations in Alzheimer's disease and age-matched healthy control cerebrospinal fluid from the Alzheimer's Disease Neuroimaging Initiative-1 baseline cohort, J Alzheimers Dis, vol.46, pp.431-440, 2015.

M. J. Savage, J. Kalinina, A. Wolfe, K. Tugusheva, R. Korn et al., A sensitive a? oligomer assay discriminates Alzheimer's and aged control cerebrospinal fluid, J Neurosci, vol.34, pp.2884-2897, 2014.

S. W. Scheff, D. A. Price, F. A. Schmitt, and E. J. Mufson, Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment, Neurobiol Aging, vol.27, pp.1372-1384, 2006.

P. Scheltens, K. Blennow, M. M. Breteler, B. De-strooper, G. B. Frisoni et al., Alzheimer's disease, Lancet, vol.388, issue.15, pp.1124-1125, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01579097

D. Scheuner, C. Eckman, M. Jensen, X. Song, M. Citron et al., Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease, Nat Med, vol.2, pp.864-870, 1996.

M. L. Schmidt, J. Murray, V. M. Lee, W. D. Hill, A. Wertkin et al., Epitope map of neurofilament protein domains in cortical and peripheral nervous system Lewy bodies, Am J Pathol, vol.139, pp.53-65, 1991.

L. S. Schneider, F. Mangialasche, N. Andreasen, H. Feldman, E. Giacobini et al., Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014, J Intern Med, vol.275, pp.251-283, 2014.

J. Schuster and S. A. Funke, Methods for the specific detection and quantitation of amyloid-? oligomers in cerebrospinal fluid, J Alzheimers Dis, vol.53, pp.53-67, 2016.

J. L. Seeburger, D. J. Holder, M. Combrinck, C. Joachim, O. Laterza et al., Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort, J Alzheimers Dis, vol.44, pp.525-539, 2015.

D. J. Selkoe and J. Hardy, The amyloid hypothesis of Alzheimer's disease at 25 years, EMBO Mol Med, vol.8, pp.595-608, 2016.

U. Sengupta, A. N. Nilson, and R. Kayed, The role of amyloid-? oligomers in toxicity, propagation, and immunotherapy, EBioMedicine, vol.6, pp.42-49, 2016.

P. Seubert, C. Vigo-pelfrey, F. Esch, M. Lee, H. Dovey et al., Isolation and quantification of soluble Alzheimer's ?-peptide from biological fluids, Nature, vol.359, pp.325-327, 1992.

J. Sevigny, P. Chiao, T. Bussiere, P. H. Weinreb, L. Williams et al., The antibody aducanumab reduces Abeta plaques in Alzheimer's disease, Nature, vol.537, pp.50-56, 2016.

P. Shahim, H. Zetterberg, Y. Tegner, and K. Blennow, Serum neurofilament light as a biomarker for mild traumatic brain injury in contact sports, Neurology, vol.88, pp.1788-1794, 2017.

M. Shahnawaz, T. Tokuda, M. Waragai, N. Mendez, R. Ishii et al., Development of a biochemical diagnosis of Parkinson disease by detection of ?-synuclein misfolded aggregates in cerebrospinal fluid, JAMA Neurol, vol.74, pp.163-172, 2017.

L. M. Shaw, H. Vanderstichele, M. Knapik-czajka, C. M. Clark, P. S. Aisen et al., Cerebrospinal fluid biomarker signature in Alzheimer's Disease neuroimaging initiative subjects, Ann Neurol, vol.65, pp.403-413, 2009.

L. M. Shaw, H. Vanderstichele, M. Knapik-czajka, M. Figurski, E. Coart et al., Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI, Acta Neuropathol, vol.121, pp.597-609, 2011.

K. S. Sheinerman, J. B. Toledo, V. G. Tsivinsky, D. Irwin, M. Grossman et al., Circulating brain-enriched microRNAs as novel biomarkers for detection and differentiation of neurodegenerative diseases, Alzheimers Res Ther, vol.9, p.89, 2017.

S. Shekhar, R. Kumar, N. Rai, V. Kumar, K. Singh et al., Estimation of tau and phosphorylated tau181 in serum of Alzheimer's disease and mild cognitive impairment patients, PLoS One, vol.11, p.99, 2016.

Y. Shen, H. Wang, Q. Sun, H. Yao, A. P. Keegan et al., Increased plasma beta-secretase 1 may predict conversion to Alzheimer's disease dementia in individuals with mild cognitive impairment, Biol Psychiatry, vol.83, pp.447-455, 2018.

M. Shi, C. P. Zabetian, A. M. Hancock, C. Ginghina, Z. Hong et al., Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease, Neurosci Lett, vol.480, pp.78-82, 2010.

R. Sims, S. J. Van-der-lee, A. C. Naj, C. Bellenguez, N. Badarinarayan et al., Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease, Nat Genet, vol.49, pp.1373-1384, 2017.

N. Singh, S. Haldar, A. K. Tripathi, K. Horback, J. Wong et al., Brain iron homeostasis: from molecular mechanisms to clinical significance and therapeutic opportunities, 2014.

, Antioxid Redox Signal, vol.20, pp.1324-1363

M. Sjögren, M. Blomberg, M. Jonsson, L. O. Wahlund, A. Edman et al., Neurofilament protein in cerebrospinal fluid: a marker of white matter changes, J Neurosci Res, vol.66, pp.510-516, 2001.

T. Skillbäck, B. Farahmand, J. W. Bartlett, C. Rosén, N. Mattsson et al., CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival, Neurology, vol.83, pp.1945-1953, 2014.

T. Skillbäck, C. Rosén, F. Asztely, N. Mattsson, K. Blennow et al., Diagnostic performance of cerebrospinal fluid total tau and phosphorylated tau in Creutzfeldt-Jakob disease: results from the Swedish Mortality Registry, JAMA Neurol, vol.71, pp.476-483, 2014.

A. Slachevsky, L. Guzmán-martínez, C. Delgado, P. Reyes, G. A. Farías et al., Tau platelets correlate with regional brain atrophy in patients with Alzheimer's disease, J Alzheimers Dis, vol.55, pp.1595-1603, 2017.

S. Slaets, L. Bastard, N. Martin, J. J. Sleegers, K. Van-broeckhoven et al., Cerebrospinal fluid A?1-40 improves differential dementia diagnosis in patients with intermediate p-tau181 levels, J Alzheimers Dis, vol.36, pp.759-767, 2013.

S. Slaets, E. Vanmechelen, L. Bastard, N. Decraemer, H. Vandijck et al., Increased CSF ?-synuclein levels in Alzheimer's disease: correlation with tau levels, Alzheimers Dement, vol.10, pp.290-298, 2014.

H. M. Snyder, R. A. Corriveau, S. Craft, J. E. Faber, S. M. Greenberg et al., Vascular contributions to cognitive impairment and dementia including Alzheimer's disease, Alzheimers Dement, vol.11, pp.710-717, 2015.

H. D. Soares, M. Gasior, J. H. Toyn, J. S. Wang, Q. Hong et al., The ?-secretase modulator, BMS-932481, modulates A? peptides in the plasma and cerebrospinal fluid of healthy volunteers, J Pharmacol Exp Ther, vol.358, pp.138-150, 2016.

L. Steardo, M. R. Bronzuoli, A. Iacomino, G. Esposito, L. Steardo et al., Does neuroinflammation turn on the flame in Alzheimer's disease? Focus on astrocytes, Front Neurosci, vol.9, p.259, 2015.

D. Strozyk, K. Blennow, L. R. White, and L. J. Launer, A? 42 levels correlate with amyloid-neuropathology in a populationbased autopsy study, Neurology, vol.60, pp.652-656, 2003.

M. Suárez-calvet, A. Caballero, M. Á. Kleinberger, G. Bateman, R. J. Fagan et al., Early changes in CSF sTREM2 in dominantly inherited Alzheimer's disease occur after amyloid deposition and neuronal injury, Sci Transl Med, vol.8, pp.369-178, 2016.

M. Suárez-calvet, O. Dols-icardo, A. Lladó, R. Sánchez-valle, I. Hernández et al., Plasma phosphorylated TDP43 levels are elevated in patients with frontotemporal dementia carrying a C9orf72 repeat expansion or a GRN mutation, J Neurol Neurosurg Psychiatry, vol.85, pp.684-691, 2014.

M. Suárez-calvet, G. Kleinberger, A. Caballero, M. Á. Brendel, M. Rominger et al., ) sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers, EMBO Mol Med, vol.8, p.6123, 2016.

C. L. Sutphen, L. Mccue, E. M. Herries, C. Xiong, J. H. Ladenson et al., Longitudinal decreases in multiple cerebrospinal fluid biomarkers of neuronal injury in symptomatic late onset Alzheimer's disease, Alzheimers Dement, vol.14, pp.869-879, 2018.

N. Suzuki, T. T. Cheung, X. D. Cai, A. Odaka, L. Otvos et al., An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants, Science, vol.264, pp.1336-1340, 1994.

N. Suzuki, T. Iwatsubo, A. Odaka, Y. Ishibashi, C. Kitada et al., High tissue content of soluble beta 1-40 is linked to cerebral amyloid angiopathy, Am J Pathol, vol.145, pp.452-460, 1994.

W. Swardfager, K. Lanctôt, L. Rothenburg, A. Wong, J. Cappell et al., A meta-analysis of cytokines in Alzheimer's disease, Biol Psychiatry, vol.68, pp.930-941, 2010.

C. I. Sze, H. Bi, B. K. Kleinschmidt-demasters, C. M. Filley, and L. J. Martin, Selective regional loss of exocytotic presynaptic vesicle proteins in Alzheimer's disease brains, J Neurol Sci, vol.175, pp.81-90, 2000.

Y. J. Tan, A. Ng, A. Vipin, J. Lim, R. J. Chander et al., Higher peripheral TREM2 mRNA levels relate to cognitive deficits and hippocampal atrophy in Alzheimer's disease and amnestic mild cognitive impairment, J Alzheimers Dis, vol.58, pp.413-423, 2017.

T. Tapiola, I. Alafuzoff, S. K. Herukka, L. Parkkinen, P. Hartikainen et al., Cerebrospinal fluid ?-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain, Arch Neurol, vol.66, pp.382-389, 2009.

R. Tarawneh, D. Angelo, G. Crimmins, D. Herries, E. Griest et al., Diagnostic and prognostic utility of the synaptic marker neurogranin in Alzheimer disease, JAMA Neurol, vol.73, pp.561-571, 2016.

R. Tarawneh, D. Angelo, G. , M. E. Xiong, C. Carter et al., Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease, Ann Neurol, vol.70, pp.274-285, 2011.

R. Tarawneh, D. Head, S. Allison, V. Buckles, A. M. Fagan et al., Cerebrospinal fluid markers of neurodegeneration and rates of brain atrophy in early Alzheimer disease, JAMA Neurol, vol.72, pp.656-665, 2015.

R. Tarawneh, J. M. Lee, J. H. Ladenson, J. C. Morris, and D. M. Holtzman, CSF VILIP-1 predicts rates of cognitive decline in early Alzheimer disease, Neurology, vol.78, pp.709-719, 2012.

H. Tatebe, T. Kasai, T. Ohmichi, Y. Kishi, T. Kakeya et al., Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case-control studies including patients with Alzheimer's disease and down syndrome, Mol Neurodegener, vol.12, p.63, 2017.

R. D. Terry, E. Masliah, D. P. Salmon, N. Butters, R. Deteresa et al., Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment, Ann Neurol, vol.30, pp.572-580, 1991.

T. Ronald and N. R. Research, Institute of the Alzheimer's Association and the National Institute on Aging Working Group (1998) Consensus report of the working group on, Neurobiol Aging, vol.19, pp.109-116

A. Thorsell, M. Bjerke, J. Gobom, E. Brunhage, E. Vanmechelen et al., Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease, Brain Res, vol.1362, pp.13-22, 2010.

M. Timmers, S. Barão, B. Van-broeck, I. Tesseur, J. Slemmon et al., BACE1 dynamics upon inhibition with a BACE inhibitor and correlation to downstream Alzheimer's disease markers in elderly healthy participants, J Alzheimers Dis, vol.56, pp.1437-1449, 2017.

G. Tirucherai, M. Ahlijanian, J. Crowell, G. Kolaitis, S. Skudalski et al., A single ascending dose study of the taudirected monoclonal antibody BMS-986168. Abstract presented at the 20th International Congress of Parkinson's Disease and Movement Disorders, pp.19-23, 2016.

T. Tokuda, M. M. Qureshi, M. T. Ardah, S. Varghese, S. A. Shehab et al., Detection of elevated levels of ?-synuclein oligomers in CSF from patients with Parkinson disease, Neurology, vol.75, pp.1766-1772, 2010.

J. B. Toledo, S. E. Arnold, K. Raible, J. Brettschneider, S. X. Xie et al., Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer's Coordinating Centre, Brain, vol.136, pp.2697-2706, 2013.

J. B. Toledo, A. Korff, L. M. Shaw, J. Q. Trojanowski, and J. Zhang, CSF alpha-synuclein improves diagnostic and prognostic performance of CSF tau and Abeta in Alzheimer's disease, Acta Neuropathol, vol.126, pp.683-697, 2013.

J. B. Toledo, S. X. Xie, J. Q. Trojanowski, and L. M. Shaw, Longitudinal change in CSF tau and A? biomarkers for up to 48 months in ADNI, Acta Neuropathol, vol.126, pp.659-670, 2013.

J. Toombs, R. W. Paterson, M. P. Lunn, J. M. Nicholas, N. C. Fox et al., Identification of an important potential confound in CSF AD studies: aliquot volume, Clin Chem Lab Med, vol.51, pp.2311-2317, 2013.

S. Tu, S. Okamoto, S. A. Lipton, and H. Xu, Oligomeric A?-induced synaptic dysfunction in Alzheimer's disease, Mol Neurodegener, vol.9, p.48, 2014.

T. Tyson, J. A. Steiner, and P. Brundin, Sorting out release, uptake and processing of alpha-synuclein during prion-like spread of pathology, J Neurochem, vol.139, issue.1, pp.275-289, 2016.

K. Y. Tzen, S. Y. Yang, T. F. Chen, T. W. Cheng, H. E. Horng et al., Plasma A? but not tau is related to brain PiB retention in early Alzheimer's disease, ACS Chem Neurosci, vol.5, pp.830-836, 2014.

J. M. Van-bergen, X. Li, J. Hua, S. J. Schreiner, S. C. Steininger et al., Colocalization of cerebral iron with amyloid beta in mild cognitive impairment, Sci Rep, vol.6, p.35514, 2016.

M. Van-oijen, A. Hofman, H. D. Soares, P. J. Koudstaal, and M. M. Breteler, Plasma A?(1-40) and A?(1-42) and the risk of dementia: a prospective case-cohort study, Lancet Neurol, vol.5, issue.06, pp.70501-70505, 2006.

I. A. Van-rossum, S. Vos, R. Handels, and P. J. Visser, Biomarkers as predictors for conversion from mild cognitive impairment to Alzheimer-type dementia: implications for trial design, J Alzheimers Dis, vol.20, pp.881-891, 2010.

H. Vanderstichele, M. Bibl, S. Engelborghs, L. Bastard, N. Lewczuk et al., Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative, Alzheimers Dement, vol.8, pp.65-73, 2012.

R. Vassar, P. H. Kuhn, C. Haass, M. E. Kennedy, L. Rajendran et al., Function, therapeutic potential and cell biology of BACE proteases: current status and future prospects, J Neurochem, vol.130, pp.4-28, 2014.

I. Verberk, R. E. Slot, S. Verfaillie, H. Heijst, N. D. Prins et al., Plasma amyloid as prescreener for the earliest Alzheimer pathological changes, Ann Neurol, 2018.

J. C. Vickers, B. M. Riederer, R. A. Marugg, V. Buee-scherrer, L. Buee et al., Alterations in neurofilament protein immunoreactivity in human hippocampal neurons related to normal aging and Alzheimer's disease, Neuroscience, vol.62, pp.1-13, 1994.

V. L. Villemagne, S. Burnham, P. Bourgeat, B. Brown, K. A. Ellis et al., Amyloid ? deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study, Lancet Neurol, vol.12, issue.13, pp.70044-70053, 2013.

G. Vivacqua, A. Latorre, A. Suppa, M. Nardi, S. Pietracupa et al., Abnormal salivary total and oligomeric alpha-synuclein in Parkinson's disease, PLoS One, vol.11, p.56, 2016.

M. J. Wang, S. Yi, J. Y. Han, S. Y. Park, J. W. Jang et al., Oligomeric forms of amyloid-? protein in plasma as a potential blood-based biomarker for Alzheimer's disease, Alzheimers Res Ther, vol.9, 2017.

Y. Wang, M. Shi, K. A. Chung, C. P. Zabetian, J. B. Leverenz et al., , 2012.

, Sci Transl Med, vol.4, issue.121

M. Waragai, M. Yoshida, M. Mizoi, R. Saiki, K. Kashiwagi et al., Increased protein-conjugated acrolein and amyloid-?40/42 ratio in plasma of patients with mild cognitive impairment and Alzheimer's disease, J Alzheimers Dis, vol.32, pp.33-41, 2012.

M. Wennström, Y. Surova, S. Hall, C. Nilsson, L. Minthon et al., The inflammatory marker YKL-40 is elevated in cerebrospinal fluid from patients with Alzheimer's but not Parkinson's disease or dementia with Lewy bodies, PLoS One, vol.10, 2015.

P. Weston, T. Poole, N. S. Ryan, A. Nair, Y. Liang et al., Serum neurofilament light in familial Alzheimer disease: a marker of early neurodegeneration, Neurology, vol.89, issue.21, pp.2167-2175, 2017.

E. Willemse, K. Van-uffelen, B. Brix, S. Engelborghs, H. Vanderstichele et al., How to handle adsorption of cerebrospinal fluid amyloid ? (1-42) in laboratory practice? Identifying problematic handlings and resolving the issue by use of the A?42/A?40 ratio, Alzheimers Dement, vol.13, pp.885-892, 2017.

S. M. Williams, P. Schulz, T. L. Rosenberry, R. J. Caselli, and M. R. Sierks, Blood-based oligomeric and other protein variant biomarkers to facilitate pre-symptomatic diagnosis and staging of Alzheimer's disease, J Alzheimers Dis, vol.58, pp.23-35, 2017.

J. Wiltfang, H. Esselmann, M. Bibl, M. Hüll, H. Hampel et al., Amyloid ? peptide ratio 42/40 but not A?42 correlates with phospho-tau in patients with low-and high-CSF A?40 load, J Neurochem, vol.101, pp.1053-1059, 2007.

C. N. Winston, E. J. Goetzl, J. C. Akers, B. S. Carter, E. M. Rockenstein et al., Prediction of conversion from mild cognitive impairment to dementia with neuronally derived blood exosome protein profile, Alzheimers Dement (Amst), vol.3, pp.63-72, 2016.

F. K. Wiseman, A. , T. Hardy, J. Karmiloff-smith, A. Nizetic et al., A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome, Nat Rev Neurosci, vol.16, pp.564-574, 2015.

G. Wu, S. Sankaranarayanan, K. Tugusheva, J. Kahana, G. Seabrook et al., Decrease in age-adjusted cerebrospinal fluid ?-secretase activity in Alzheimer's subjects, Clin Biochem, vol.41, pp.986-996, 2008.

G. Wu, S. Sankaranarayanan, J. Wong, K. Tugusheva, M. S. Michener et al., Characterization of plasma ?-secretase (BACE1) activity and soluble amyloid precursor proteins as potential biomarkers for Alzheimer's disease, J Neurosci Res, vol.90, pp.2247-2258, 2012.

R. Yan, Physiological functions of the ?-site amyloid precursor protein cleaving enzyme 1 and 2, Front Mol Neurosci, vol.10, p.97, 2017.

C. C. Yang, M. J. Chiu, T. F. Chen, H. L. Chang, B. H. Liu et al., Assay of plasma phosphorylated tau protein (threonine 181) and total tau protein in early-stage Alzheimer's disease, J Alzheimers Dis, vol.61, pp.1323-1332, 2018.

T. Yang, O. Malley, T. T. Kanmert, D. Jerecic, J. Zieske et al., A highly sensitive novel immunoassay specifically detects low levels of soluble Abeta oligomers in human cerebrospinal fluid, Alzheimers Res Ther, vol.7, 2015.

Y. Yoshiyama, M. Higuchi, B. Zhang, S. M. Huang, N. Iwata et al., Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model, Neuron, vol.53, pp.337-351, 2007.

A. Yuan, M. V. Rao, V. Nixon, and R. A. , Neurofilaments at a glance, J Cell Sci, vol.125, pp.3257-3263, 2012.

A. Yuan, M. V. Rao, V. Nixon, and R. A. , Neurofilaments and neurofilament proteins in health and disease, Cold Spring Harb Perspect Biol, vol.9, 2017.

P. Yuan, C. Condello, C. D. Keene, Y. Wang, T. D. Bird et al., TREM2 haplodeficiency in mice and humans impairs the microglia barrier function leading to decreased amyloid compaction and severe axonal dystrophy, Neuron, vol.92, pp.252-264, 2016.

H. Zetterberg, U. Andreasson, O. Hansson, G. Wu, S. Sankaranarayanan et al., Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease, Arch Neurol, vol.65, pp.1102-1107, 2008.

H. Zetterberg, M. Pedersen, K. Lind, M. Svensson, S. Rolstad et al., Intra-individual stability of CSF biomarkers for Alzheimer's disease over two years, J Alzheimers Dis, vol.12, pp.255-260, 2007.

H. Zetterberg, T. Skillbäck, N. Mattsson, J. Q. Trojanowski, E. Portelius et al., Association of cerebrospinal fluid neurofilament light concentration with Alzheimer disease progression, JAMA Neurol, vol.73, pp.60-67, 2016.

H. Zetterberg, D. Wilson, U. Andreasson, L. Minthon, K. Blennow et al., Plasma tau levels in Alzheimer's disease, Alzheimers Res Ther, vol.5, p.9, 2013.

B. Zhang, J. Carroll, J. Q. Trojanowski, Y. Yao, M. Iba et al., The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice, J Neurosci, vol.32, pp.3601-3611, 2012.

Q. S. Zhang, Y. Heng, Y. H. Yuan, and N. H. Chen, Pathological ?-synuclein exacerbates the progression of Parkinson's disease through microglial activation, Toxicol Lett, vol.265, pp.30-37, 2017.

Z. Zhong, M. Ewers, S. Teipel, K. Bürger, A. Wallin et al., Levels of ?-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment, Arch Gen Psychiatry, vol.64, pp.718-726, 2007.

W. Zhou, J. Zhang, F. Ye, G. Xu, H. Su et al., Plasma neurofilament light chain levels in Alzheimer's disease, Neurosci Lett, vol.650, pp.60-64, 2017.